Company intelligence / Profile preview

Yates Ohana

Cambridge, Massachusetts, United Statescharterindex.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The lead product, OHB035—a sperm preparation kit for IVF—is in a randomized controlled trial with the goal of improving pregnancy rates by enhancing sperm ex vivo. A non-hormonal male contraceptive drug is also under preclinical development. The company's approach aims to reduce IVF cycles needed for success and lower risk of inherited disease or pregnancy complications by selecting healthy sperm[1][2].

Therapeutic areas: Men's HealthRare DiseasesWomen's Health
Modalities: Sperm enhancement (ex vivo manipulation)Non-hormonal contraception (in development)
Industry: Biotech

Drug pipeline

2 assets

S-1117

Pre-clinical

Indications: Immune thrombocytopenia

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships publicly disclosed as of last update.

Beyond the preview

Go deeper on Yates Ohana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yates Ohana.

Explore the full profile